Leveraged & Inverse ChannelUp Over 100% in 2020 and 15% in 2021, ‘LABU’ Isn’t Holding BackBy Ben HernandezJanuary 12, 2021
Leveraged & Inverse Channel3 Direxion ETFs Top List of Best Leveraged PerformersBy Ben HernandezDecember 22, 2020
Leveraged & Inverse ChannelShort Sellers Back Off From Biotech ETFsBy Ben HernandezSeptember 28, 2020
Leveraged & Inverse ChannelCOVID Trade: The Race for an Ounce of PreventionBy DirexionAugust 21, 2020
Leveraged & Inverse ChannelBiotech Has Been in a Steady Uptrend Even Through Covid-19By Ben HernandezAugust 20, 2020
Leveraged & Inverse ChannelTraders Can Look to Biotech ETFs to For a Potential Virus CureBy Ben HernandezMay 19, 2020
Leveraged & Inverse ChannelConsider These 2 Leveraged Biotech ETFs to Ride The M&A TrendBy Ian YoungDecember 13, 2019
Leveraged & Inverse Channel5 Leveraged ETFs With Biggest 1-Month Fund FlowsBy Ben HernandezMay 22, 2019
Leveraged & Inverse Channel5 Best-Performing Leveraged ETFs Year-to-DateBy Ben HernandezMarch 29, 2019
Leveraged & Inverse ChannelBig Biopharma Mergers Could Fuel These ETFs in 2019By Ben HernandezJanuary 10, 2019
Leveraged & Inverse ChannelBiotech ETFs Hoping This Post-Election Trend Doesn’t RepeatBy Brenton GarenNovember 8, 2018
Leveraged & Inverse ChannelAfter a Rough October, Leveraged Biotech ETF Looks to Bounce BackBy Brenton GarenNovember 6, 2018
